3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Plasma cell
2
Myeloid
2
Lymphoid
2
Gastrointestinal
2
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Classical hematology
1
CNS
1
Breast
1
Conditions
Melanoma
71
Neoplasms
10
Skin Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
2
Brain Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Skin Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Laryngeal Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
3
trametinib
2
pertuzumab
2
dabrafenib
2
Trastuzumab
2
Tacrolimus
2
Specimen Handling
2
Polymerase Chain Reaction
2
Nivolumab
2
Biopsy
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
tinostamustine
1
temsirolimus
1
sonidegib
1
selinexor
1
sapanisertib
1
romidepsin
1
relatlimab
1
palbociclib
1
osimertinib
1
omipalisib
1
merphos
1
larotrectinib
1
ipatasertib
1
fludarabine phosphate
1
erdafitinib
1
entrectinib
1
defactinib
1
copanlisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Vemurafenib
×
Dermatologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled